Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
Status:
Recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
BTK inhibition and checkpoint blockade are promising classes of therapy for central nervous
system (CNS) lymphoma and have demonstrated efficacy with acceptable toxicity. A multidrug
approach may carry a higher chance of durable efficacy in this aggressive disease that
carries significant morbidity and mortality. Given the poor outcomes and limited options for
patients who are not candidates for high-dose methotrexate, the investigators seek to
evaluate the combination in this patient population.